{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:16:36Z","timestamp":1793276196546,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02029-9","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T07:09:13Z","timestamp":1744960153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Enhancement of the endocannabinoid system through monoacylglycerol lipase inhibition relieves migraine-associated pain in mice"],"prefix":"10.1186","volume":"26","author":[{"given":"Elizaveta","family":"Mangutov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaseen","family":"Awad-Igbaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Siegersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Gastambide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodeji A.","family":"Asuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9691-2976","authenticated-orcid":false,"given":"Amynah A. A.","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"2029_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Lifting the burden: the global campaign against H. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137","journal-title":"J Headache Pain"},{"key":"2029_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/head.14024","volume":"61","author":"R Burch","year":"2021","unstructured":"Burch R, Rizzoli P, Loder E (2021) The prevalence and impact of migraine and severe headache in the united States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache 61:60\u201368","journal-title":"Headache"},{"key":"2029_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP et al (2021) Migraine: epidemiology and systems of care. Lancet 397:1485\u20131495","journal-title":"Lancet"},{"key":"2029_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.13459","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Greisman JD, Baigi K, Lipton RB (2019) Migraine progression: A systematic review. Headache 59:306\u2013338","journal-title":"Headache"},{"key":"2029_CR5","doi-asserted-by":"crossref","unstructured":"ICHD. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia (2013);33:629\u2013808","DOI":"10.1177\/0333102413485658"},{"key":"2029_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0333102414552532","volume":"35","author":"AM Adams","year":"2015","unstructured":"Adams AM, Serrano D, Buse DC et al (2015) The impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) study methods and baseline results. Cephalalgia 35:563\u2013578","journal-title":"Cephalalgia"},{"key":"2029_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/head.14709","volume":"64","author":"F Cohen","year":"2024","unstructured":"Cohen F, Brooks CV, Sun D et al (2024) Prevalence and burden of migraine in the united States: A systematic review. Headache 64:516\u2013532","journal-title":"Headache"},{"key":"2029_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1468-2982.2007.01288.x","volume":"27","author":"L Stovner","year":"2007","unstructured":"Stovner L, Hagen K, Jensen R et al (2007) The global burden of headache: a Documentation of headache prevalence and disability worldwide. Cephalalgia 27:193\u2013210","journal-title":"Cephalalgia"},{"key":"2029_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71:559\u2013566","journal-title":"Neurology"},{"key":"2029_CR10","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3389\/fphar.2018.00420","volume":"9","author":"P Leimuranta","year":"2018","unstructured":"Leimuranta P, Khiroug L, Giniatullin R (2018) Emerging role of (Endo)Cannabinoids in migraine. Front Pharmacol 9:420","journal-title":"Front Pharmacol"},{"key":"2029_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"HC Lu","year":"2016","unstructured":"Lu HC, Mackie K (2016) An introduction to the endogenous cannabinoid system. Biol Psychiatry 79:516\u2013525","journal-title":"Biol Psychiatry"},{"key":"2029_CR12","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S0026-895X(24)26516-0","volume":"57","author":"W Gonsiorek","year":"2000","unstructured":"Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW (2000) Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by Anandamide. Mol Pharmacol 57:1045\u20131050","journal-title":"Mol Pharmacol"},{"key":"2029_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.bjp.0704297","volume":"134","author":"JR Savinainen","year":"2001","unstructured":"Savinainen JR, Jarvinen T, Laine K, Laitinen JT (2001) Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes. Br J Pharmacol 134:664\u2013672","journal-title":"Br J Pharmacol"},{"key":"2029_CR14","first-page":"e17407","volume":"13","author":"S Poudel","year":"2021","unstructured":"Poudel S, Quinonez J, Choudhari J et al (2021) Medical cannabis, headaches, and migraines: A review of the current literature. Cureus 13:e17407","journal-title":"Cureus"},{"key":"2029_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/can.2016.0010","volume":"1","author":"C Cuttler","year":"2016","unstructured":"Cuttler C, Mischley LK, Sexton M (2016) Sex differences in cannabis use and effects: A Cross-Sectional survey of cannabis users. Cannabis Cannabinoid Res 1:166\u2013175","journal-title":"Cannabis Cannabinoid Res"},{"key":"2029_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/phar.1673","volume":"36","author":"DN Rhyne","year":"2016","unstructured":"Rhyne DN, Anderson SL, Gedde M, Borgelt LM (2016) Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacotherapy 36:505\u2013510","journal-title":"Pharmacotherapy"},{"key":"2029_CR17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/j.1526-4610.2008.01217.x","volume":"48","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB (2008) Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48:1157\u20131168","journal-title":"Headache"},{"key":"2029_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/0269881117699616","volume":"31","author":"BJ Piper","year":"2017","unstructured":"Piper BJ, DeKeuster RM, Beals ML et al (2017) Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol 31:569\u2013575","journal-title":"J Psychopharmacol"},{"key":"2029_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00228-007-0391-4","volume":"64","author":"C Rossi","year":"2008","unstructured":"Rossi C, Pini LA, Cupini ML, Calabresi P, Sarchielli P (2008) Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol 64:1\u20138","journal-title":"Eur J Clin Pharmacol"},{"key":"2029_CR20","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/sj.npp.1301246","volume":"32","author":"P Sarchielli","year":"2007","unstructured":"Sarchielli P, Pini LA, Coppola F et al (2007) Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology 32:1384\u20131390","journal-title":"Neuropsychopharmacology"},{"key":"2029_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1468-2982.2005.01031.x","volume":"26","author":"LM Cupini","year":"2006","unstructured":"Cupini LM, Bari M, Battista N et al (2006) Biochemical changes in endocannabinoid system are expressed in platelets of female but not male migraineurs. Cephalalgia 26:277\u2013281","journal-title":"Cephalalgia"},{"key":"2029_CR22","doi-asserted-by":"crossref","unstructured":"Lo Castro F, Baraldi C, Pellesi L, Guerzoni S (2022) Clinical evidence of cannabinoids in migraine: A narrative review. J Clin Med.;11","DOI":"10.3390\/jcm11061479"},{"key":"2029_CR23","doi-asserted-by":"publisher","first-page":"102619","DOI":"10.1016\/j.ctim.2020.102619","volume":"56","author":"LP Gibson","year":"2021","unstructured":"Gibson LP, Hitchcock LN, Bryan AD, Bidwell LC (2021) Experience of migraine, its severity, and perceived efficacy of treatments among cannabis users. Complement Ther Med 56:102619","journal-title":"Complement Ther Med"},{"key":"2029_CR24","doi-asserted-by":"crossref","unstructured":"Rangari VA, O\u2019Brien ES, Powers AS et al (2025) A cryptic pocket in CB1 drives peripheral and functional selectivity. Nature 640(8057):265\u2013273","DOI":"10.1038\/s41586-025-08618-7"},{"key":"2029_CR25","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/0333102414566862","volume":"35","author":"R Greco","year":"2015","unstructured":"Greco R, Bandiera T, Mangione AS et al (2015) Effects of peripheral FAAH Blockade on NTG-induced hyperalgesia\u2013evaluation of URB937 in an animal model of migraine. Cephalalgia 35:1065\u20131076","journal-title":"Cephalalgia"},{"key":"2029_CR26","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.euroneuro.2015.04.001","volume":"25","author":"C Nozaki","year":"2015","unstructured":"Nozaki C, Markert A, Zimmer A (2015) Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice. Eur Neuropsychopharmacol 25:1388\u20131396","journal-title":"Eur Neuropsychopharmacol"},{"key":"2029_CR27","doi-asserted-by":"crossref","unstructured":"Della Pietra A, Giniatullin R, Savinainen JR (2021) Distinct activity of Endocannabinoid-Hydrolyzing enzymes MAGL and FAAH in key regions of peripheral and central nervous system implicated in migraine. Int J Mol Sci.;22","DOI":"10.3390\/ijms22031204"},{"key":"2029_CR28","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1177\/0333102417727537","volume":"38","author":"R Greco","year":"2018","unstructured":"Greco R, Demartini C, Zanaboni AM, Berliocchi L, Piomelli D, Tassorelli C (2018) Inhibition of monoacylglycerol lipase: another signalling pathway for potential therapeutic targets in migraine? Cephalalgia 38:1138\u20131147","journal-title":"Cephalalgia"},{"key":"2029_CR29","doi-asserted-by":"crossref","unstructured":"Greco R, Demartini C, Francavilla M, Zanaboni AM, Tassorelli C (2021) Dual Inhibition of FAAH and MAGL counteracts migraine-like pain and behavior in an animal model of migraine. Cells 10:2543","DOI":"10.3390\/cells10102543"},{"key":"2029_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s10194-023-01568-3","volume":"24","author":"A Della Pietra","year":"2023","unstructured":"Della Pietra A, Krivoshein G, Ivanov K et al (2023) Potent dual MAGL\/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain. J Headache Pain 24:38","journal-title":"J Headache Pain"},{"key":"2029_CR31","doi-asserted-by":"publisher","first-page":"1171188","DOI":"10.3389\/fpain.2023.1171188","volume":"4","author":"E Liktor-Busa","year":"2023","unstructured":"Liktor-Busa E, Levine AA, Palomino SM et al (2023) ABHD6 and MAGL control 2-AG levels in the PAG and allodynia in a CSD-induced periorbital model of headache. Front Pain Res (Lausanne) 4:1171188","journal-title":"Front Pain Res (Lausanne)"},{"key":"2029_CR32","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1038\/s41467-023-43606-3","volume":"14","author":"M Jiang","year":"2023","unstructured":"Jiang M, Huizenga MCW, Wirt JL et al (2023) A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence. Nat Commun 14:8039","journal-title":"Nat Commun"},{"key":"2029_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1124\/jpet.118.252296","volume":"367","author":"JR Clapper","year":"2018","unstructured":"Clapper JR, Henry CL, Niphakis MJ et al (2018) Monoacylglycerol lipase Inhibition in human and rodent systems supports clinical evaluation of endocannabinoid modulators. J Pharmacol Exp Ther 367:494\u2013508","journal-title":"J Pharmacol Exp Ther"},{"key":"2029_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1468-2982.2009.01864.x","volume":"30","author":"EA Bates","year":"2010","unstructured":"Bates EA, Nikai T, Brennan KC et al (2010) Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia 30:170\u2013178","journal-title":"Cephalalgia"},{"key":"2029_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.pain.2013.10.004","volume":"155","author":"AA Pradhan","year":"2014","unstructured":"Pradhan AA, Smith ML, McGuire B, Tarash I, Evans CJ, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155:269\u2013274","journal-title":"Pain"},{"key":"2029_CR36","doi-asserted-by":"crossref","unstructured":"Bertels Z, Singh H, Dripps I et al (2021) Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 Inhibition. eLife.;10","DOI":"10.7554\/eLife.63076"},{"key":"2029_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neuropharm.2018.12.017","volume":"148","author":"LS Moye","year":"2019","unstructured":"Moye LS, Tipton AF, Dripps I et al (2019) Delta opioid receptor agonists are effective for multiple types of headache disorders. Neuropharmacology 148:77\u201386","journal-title":"Neuropharmacology"},{"key":"2029_CR38","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1177\/0333102417737778","volume":"38","author":"M Ben Aissa","year":"2018","unstructured":"Ben Aissa M, Tipton AF, Bertels Z et al (2018) Soluble Guanylyl cyclase is a critical regulator of migraine-associated pain. Cephalalgia 38:1471\u20131484","journal-title":"Cephalalgia"},{"key":"2029_CR39","doi-asserted-by":"crossref","unstructured":"Mangutov E, Dripps I, Siegersma K et al (2025) Activation of \u03b4-opioid receptors blocks allodynia in a model of headache induced by PACAP. Br J Pharmacol 182:1630\u20131643","DOI":"10.1111\/bph.17424"},{"key":"2029_CR40","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/head.14517","volume":"63","author":"HR Mei","year":"2023","unstructured":"Mei HR, Hu YY, Kapadia S, Ouimet T, Poras H, Dussor G (2023) Efficacy of dual enkephalinase Inhibition in a preclinical migraine model is mediated by activation of peripheral delta opioid receptors. Headache 63:621\u2013633","journal-title":"Headache"},{"key":"2029_CR41","doi-asserted-by":"crossref","unstructured":"Zhu D, Zhang J, Ma X et al (2024) Overabundant endocannabinoids in neurons are detrimental to cognitive function. BioRxiv 17:2024.09.17.613513","DOI":"10.1101\/2024.09.17.613513"},{"key":"2029_CR42","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/nn.2616","volume":"13","author":"JE Schlosburg","year":"2010","unstructured":"Schlosburg JE, Blankman JL, Long JZ et al (2010) Chronic monoacylglycerol lipase Blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13:1113\u20131119","journal-title":"Nat Neurosci"},{"key":"2029_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s10194-024-01817-z","volume":"25","author":"J Wen","year":"2024","unstructured":"Wen J, Tanaka M, Zhang Y (2024) Inhibition of 2-AG hydrolysis alleviates posttraumatic headache attributed to mild traumatic brain injury. J Headache Pain 25:115","journal-title":"J Headache Pain"},{"key":"2029_CR44","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0306-4522(03)00333-6","volume":"120","author":"TJ Price","year":"2003","unstructured":"Price TJ, Helesic G, Parghi D, Hargreaves KM, Flores CM (2003) The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. Neuroscience 120:155\u2013162","journal-title":"Neuroscience"},{"key":"2029_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s10194-022-01399-8","volume":"23","author":"IM Christiansen","year":"2022","unstructured":"Christiansen IM, Edvinsson JCA, Reducha PV, Edvinsson L, Haanes KA (2022) Dual action of the cannabinoid receptor 1 ligand arachidonyl-2\u2019-chloroethylamide on calcitonin gene-related peptide release. J Headache Pain 23:30","journal-title":"J Headache Pain"},{"key":"2029_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s10194-024-01883-3","volume":"25","author":"E Zorrilla","year":"2024","unstructured":"Zorrilla E, Della Pietra A, Russo AF (2024) Interplay between cannabinoids and the neuroimmune system in migraine. J Headache Pain 25:178","journal-title":"J Headache Pain"},{"key":"2029_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bone.2019.05.015","volume":"127","author":"LCV Alves","year":"2019","unstructured":"Alves LCV, Lisboa MRP, da Silveira HF et al (2019) Electroacupuncture increases Immunoexpression of CB1 and CB2 receptors in experimental model of inflammatory bone loss. Bone 127:59\u201366","journal-title":"Bone"},{"key":"2029_CR48","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.expneurol.2010.03.029","volume":"224","author":"R Greco","year":"2010","unstructured":"Greco R, Gasperi V, Maccarrone M, Tassorelli C (2010) The endocannabinoid system and migraine. Exp Neurol 224:85\u201391","journal-title":"Exp Neurol"},{"key":"2029_CR49","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3389\/fnins.2018.00172","volume":"12","author":"R Greco","year":"2018","unstructured":"Greco R, Demartini C, Zanaboni AM, Piomelli D, Tassorelli C (2018) Endocannabinoid system and migraine pain: an update. Front Neurosci 12:172","journal-title":"Front Neurosci"},{"key":"2029_CR50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1468-2982.2009.01924.x","volume":"30","author":"R Greco","year":"2010","unstructured":"Greco R, Gasperi V, Sandrini G et al (2010) Alterations of the endocannabinoid system in an animal model of migraine: evaluation in cerebral areas of rat. Cephalalgia 30:296\u2013302","journal-title":"Cephalalgia"},{"key":"2029_CR51","doi-asserted-by":"publisher","first-page":"615028","DOI":"10.3389\/fphar.2020.615028","volume":"11","author":"A Levine","year":"2020","unstructured":"Levine A, Liktor-Busa E, Karlage KL et al (2020) DAGLalpha Inhibition as a Non-invasive and translational model of episodic headache. Front Pharmacol 11:615028","journal-title":"Front Pharmacol"},{"key":"2029_CR52","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40122-024-00690-7","volume":"14","author":"L Dong","year":"2025","unstructured":"Dong L, Dong W, Jin Y, Jiang Y, Li Z, Yu D (2025) The global burden of migraine: A 30-Year trend review and future projections by age, sex, country, and region. Pain Ther 14:297\u2013315","journal-title":"Pain Ther"},{"key":"2029_CR53","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.intimp.2018.09.006","volume":"64","author":"SL Cruz","year":"2018","unstructured":"Cruz SL, Sanchez-Miranda E, Castillo-Arellano JI, Cervantes-Villagrana RD, Ibarra-Sanchez A, Gonzalez-Espinosa C (2018) Anandamide inhibits FcepsilonRI-dependent degranulation and cytokine synthesis in mast cells through CB(2) and GPR55 receptor activation. Possible involvement of CB(2)-GPR55 heteromers. Int Immunopharmacol 64:298\u2013307","journal-title":"Int Immunopharmacol"},{"key":"2029_CR54","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","volume":"20","author":"EC Agostoni","year":"2019","unstructured":"Agostoni EC, Barbanti P, Calabresi P et al (2019) Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain 20:92","journal-title":"J Headache Pain"},{"key":"2029_CR55","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1124\/jpet.118.252288","volume":"367","author":"RA Slivicki","year":"2018","unstructured":"Slivicki RA, Saberi SA, Iyer V, Vemuri VK, Makriyannis A, Hohmann AG (2018) Brain-Permeant and -Impermeant inhibitors of fatty acid amide hydrolase synergize with the opioid analgesic morphine to suppress Chemotherapy-Induced neuropathic nociception without enhancing effects of morphine on Gastrointestinal transit. J Pharmacol Exp Ther 367:551\u2013563","journal-title":"J Pharmacol Exp Ther"},{"key":"2029_CR56","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1124\/mol.115.098483","volume":"88","author":"L Deng","year":"2015","unstructured":"Deng L, Cornett BL, Mackie K, Hohmann AG (2015) CB1 knockout mice unveil sustained CB2-Mediated antiallodynic effects of the mixed CB1\/CB2 agonist CP55,940 in a mouse model of Paclitaxel-Induced neuropathic pain. Mol Pharmacol 88:64\u201374","journal-title":"Mol Pharmacol"},{"key":"2029_CR57","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/j.1526-4610.2011.01986.x","volume":"51","author":"EW Loder","year":"2011","unstructured":"Loder EW, Rizzoli P (2011) Tolerance and loss of beneficial effect during migraine prophylaxis: clinical considerations. Headache 51:1336\u20131345","journal-title":"Headache"},{"key":"2029_CR58","doi-asserted-by":"publisher","first-page":"333102424123513","DOI":"10.1177\/03331024241235139","volume":"44","author":"AR Shewale","year":"2024","unstructured":"Shewale AR, Brandenburg JA, Burslem K, Lipton RB, Doshi JA (2024) Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine. Cephalalgia 44:3331024241235139","journal-title":"Cephalalgia"},{"key":"2029_CR59","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1093\/brain\/awaa211","volume":"143","author":"C Saengjaroentham","year":"2020","unstructured":"Saengjaroentham C, Strother LC, Dripps I et al (2020) Differential medication overuse risk of novel anti-migraine therapeutics. Brain 143:2681\u20132688","journal-title":"Brain"},{"key":"2029_CR60","doi-asserted-by":"publisher","first-page":"333102423116126","DOI":"10.1177\/03331024231161261","volume":"43","author":"T Asawavichienjinda","year":"2023","unstructured":"Asawavichienjinda T, Sathitratanacheewin S, Chokesuwattanaskul R (2023) Wearing-off efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials. Cephalalgia 43:3331024231161261","journal-title":"Cephalalgia"},{"key":"2029_CR61","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/mds.28681","volume":"36","author":"KR Muller-Vahl","year":"2021","unstructured":"Muller-Vahl KR, Fremer C, Beals C, Ivkovic J, Loft H, Schindler C (2021) Monoacylglycerol lipase Inhibition in tourette syndrome: A 12-Week, randomized, controlled study. Mov Disord 36:2413\u20132418","journal-title":"Mov Disord"},{"key":"2029_CR62","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1055\/a-1675-3494","volume":"55","author":"KR Muller-Vahl","year":"2022","unstructured":"Muller-Vahl KR, Fremer C, Beals C, Ivkovic J, Loft H, Schindler C (2022) Endocannabinoid modulation using monoacylglycerol lipase Inhibition in tourette syndrome: A phase 1 randomized, Placebo-Controlled study. Pharmacopsychiatry 55:148\u2013156","journal-title":"Pharmacopsychiatry"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02029-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02029-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02029-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T08:01:51Z","timestamp":1744963311000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02029-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2029"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02029-9","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed according to the Association for Assessment and Accreditation of Laboratory Animal Care guidelines administered by the University of Illinois at Chicago and Washington University School of Medicine Animal Care Committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Two of the authors (FG and AAA) are employees of Lundbeck. However, they did not collect or analyze data nor did they influence it in any way.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}